Aerie's Netarsudil's Safety Questions May Determine Fate At Advisory Committee
Proposed treatment for elevated intraocular pressure would be first in new rho-associated protein kinase inhibitor class.
You may also be interested in...
The agency's Dec. 21 approval of Giapreza became novel drug No. 46 of 2017, topping the 2015 mark of 45.
The first of Aerie's two glaucoma candidates, Rhopressa, was approved in the US and a submission for combination product Roclatan is expected next year. Rhopressa may have muted uptake in 2018, however, since it won't launch until the second quarter and half of its market is covered by Medicare Part D.
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.